$96.55
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The company is headquartered in Warsaw Indiana, Indiana and currently employs 17,000 full-time employees. The company went IPO on 2001-07-25. The company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. The company also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
Country

US

CEO

Mr. Ivan Tornos

IPO date

2001

Employees

17,000

ISIN

US98956P1021

Key stats

Open

$96.60

Volume

2.19M

Market cap

$18.37B

Prev. close

$96.55

Impl / hst vl

-

Open interest

$0.00

$96.55

Day’s Range

$96.60

$79.12

52W Range

$101.80

Valuation

61
Valuation score
Undervalued
P/E
23.32
P/S
2.21
P/B
1.49
Current ratio
1.69
Debt / Equity
0.59
ROE
6.35%
Gross margin
70.81%
Income growth
-16.72%
FCF growth
18.85

Jul

31

Dividends

The last payment date was Jul 31, 2026

Div. per Share

$0.24

Div. Yield

0.25%

Payout Ratio

23.37%

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Hold

The average rating from top 22 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$101.71
The top 24 analysts forecasts that 12-month price may increase by 5.35%, with a low of $83.83 and a high of $135.57
$83.83
Low
$101.71
Avg
$135.57
High
Current price

Earnings

Q2 ‘26 revenue
$2.18B
Q2 ‘26 net income
$198.30M
Revenue
Net income
Previous EPS
$2.09
Estimate EPS
$2.03
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply